Figure 2.
Representative time line of serologic response to rituximab in one patient. The trend in antibody titers against 3 antigens (DBY ♦, UTY ▪, and EBV ▴) before and after administration of rituximab (vertical arrows) is demonstrated by the trend lines (added for clarity). The clinical time course of chronic GVHD is depicted along the x-axis.